Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brief Admission for Adolescents Who Self-harm

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04962373
Recruitment Status : Recruiting
First Posted : July 15, 2021
Last Update Posted : July 16, 2021
Sponsor:
Collaborator:
Lund University
Information provided by (Responsible Party):
Sofie Westling, Region Skane

Brief Summary:

There is still no consensus on how to manage suicidal behavior in youth with recurrent self-harm at times when the risk for suicide is imminent (1). Brief Admission (BA) has evolved as a promising crisis intervention for adults with self-harm (2). The characteristics of BA is different from other types of admission, being focused on prevention through increased autonomy and self-care, based on structured and voluntary brief self-referrals to hospital (3). As a result of a randomized controlled trial, BA is since January 2019, continuously offered to adults with self-harm at risk for suicide in Skåne (4). Parallel to this clinical trial, the method has been adapted to work in a psychiatric setting for adolescents. At present 24 adolescents have access to the method in Skåne. Clinical experiences from staff are promising, however, the lived experiences have not been collected in a standardized way.

The aim of the present study is to gather information on how BA in its present, standardized form works for adolescents, their loved ones and staff working at the ward providing BA. This will be done through semi-structured interviews with:

  1. Adolescents using BA and their loved ones
  2. Staff working at the ward providing BA. Data will be analyzed with qualitative analysis (5, 6). The ultimate aim is to use these results to optimize the current standardized version of BA for adolescents in order to test in a randomized clinical trial.

Condition or disease Intervention/treatment
Self-Harm, Deliberate Suicide, Attempted Suicidal Non-Suicidal Self Injury Other: Semi-structured interviews

Layout table for study information
Study Type : Observational
Estimated Enrollment : 75 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Brief Admission by Self-referral for Adolescents Who Self-harm, at Risk for Suicide. A Qualitative Study to Optimise and Standardise the Intervention
Actual Study Start Date : September 1, 2020
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Self-Harm Suicide

Group/Cohort Intervention/treatment
Adolescents
Adolescents with a contract for Brief admission by self-referral
Other: Semi-structured interviews
Each participant will attend a 30-60 minute semi-structured interview conducted by the CI

Parents
Parents to adolescents with a contract for Brief admission by self-referral
Other: Semi-structured interviews
Each participant will attend a 30-60 minute semi-structured interview conducted by the CI

Staff
Health care providers who work with adolescents with a contract for Brief admission by self-referral
Other: Semi-structured interviews
Each participant will attend a 30-60 minute semi-structured interview conducted by the CI




Primary Outcome Measures :
  1. Perceived effective components of Brief Admission for adolescents [ Time Frame: 60mins ]
    Qualitative data from interviews

  2. Potential adaptations of the method to better fit adolescents [ Time Frame: 60mins ]
    Qualitative data from interviews

  3. Areas where Brief Admission have the most prominent perceived effects in adolescents [ Time Frame: 60mins ]
    Qualitative data from interviews



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years to 100 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adolescents with an active BA contract, their loved ones who have given informed consent to participate and psychiatric staff working with the adolescents.
Criteria

Sample 1:

Inclusion Criteria:

  • Adolescents with an active BA contract
  • At least 13 years of age.
  • Able to consent to study participation through written and oral information.
  • Consent from caregivers
  • Given consent to participate

Exclusion Criteria:

  • Below the age of 13.

Sample 2:

Inclusion Criteria:

  • Parents to adolescents with an active BA contract
  • At least 18 years of age.
  • Able to consent to study participation through written and oral information.
  • Given consent to participate

Exclusion Criteria:

  • None

Sample 3:

Inclusion Criteria:

  • Staff working with adolescents with an active BA contract
  • At least 18 years of age.
  • Able to consent to study participation through written and oral information.
  • Given consent to participate

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04962373


Contacts
Layout table for location contacts
Contact: Sofie Westling, MD PhD +46735626099 sofie.westling@med.lu.se
Contact: Kajsa Landgren, RN PhD +46739321746 kajsa.landgren@med.lu.se

Locations
Layout table for location information
Sweden
Psykiatri och habilitering, Region Skåne Recruiting
Lund, Skåne, Sweden, 22185
Contact: Sofie Westling, MD PhD    +46735626099    sofie.westling@med.lu.se   
Contact: Kajsa Landgren, RN PhD    +46739321746    kajsa.landgren@med.lu.se   
Sponsors and Collaborators
Region Skane
Lund University
Publications:

Layout table for additonal information
Responsible Party: Sofie Westling, Principal Investigator, Region Skane
ClinicalTrials.gov Identifier: NCT04962373    
Other Study ID Numbers: 2020-01840
First Posted: July 15, 2021    Key Record Dates
Last Update Posted: July 16, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data is qualitative, transcriptions from interviews. Even if personal identifiers are removed, it is difficult to ensure enough secrecy/privacy for the participants.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Suicide
Self-Injurious Behavior
Suicide, Attempted
Behavioral Symptoms